Apriso is an anti-inflammatory medication primarily used for the treatment of ulcerative colitis. It is manufactured by Valeant Pharma Intl, contains the active ingredient mesalamine, and was first authorized for market use on October 31, 2008. Apriso comes in an extended-release oral capsule form.
The patent for Apriso is set to expire on May 1, 2030. This means that generic versions of Apriso could be available after this date, assuming there are no patent litigations or other forms of market exclusivity that may delay generic release.
Apriso is used for the maintenance of remission of ulcerative colitis. Its active ingredient, mesalamine, works by reducing inflammation in the colon, alleviating the symptoms of ulcerative colitis.
Apriso holds a single patent (US8865688) dedicated to the 'Compositions and methods for the treatment of bowel diseases with granulated Mesalamine'. This patent is set to expire on May 1, 2030. Below are the details of the patent: